Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has provided an announcement.
SanBio Co., Ltd. announced the issuance of new shares through an international offering to fund the launch and marketing of its product AKUUGO® in Japan and to support clinical trials in the U.S. and Japan. This strategic move aims to enhance the company’s growth and corporate value by establishing necessary infrastructure and expanding its market presence in regenerative medicine.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell therapies. Its primary product, SB623, is designed to improve motor, sensory, and cognitive functions by promoting the body’s natural regenerative processes. The company is particularly focused on addressing conditions such as traumatic brain injuries and cerebral infarctions.
Average Trading Volume: 2,779,301
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen204.9B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.